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Purpose: We compared patterns of visual field loss detected by standard automated
perimetry (SAP) to saccadic vector optokinetic perimetry (SVOP) and examined patient
perceptions of each test.
Methods: A cross-sectional study was done of 58 healthy subjects and 103 with
glaucoma who were tested using SAP and two versions of SVOP (v1 and v2). Visual
fields from both devices were categorized by masked graders as: 0, normal; 1,
paracentral defect; 2, nasal step; 3, arcuate defect; 4, altitudinal; 5, biarcuate; and 6,
end-stage field loss. SVOP and SAP classifications were cross-tabulated. Subjects
completed a questionnaire on their opinions of each test.
Results: We analyzed 142 (v1) and 111 (v2) SVOP and SAP test pairs. SVOP v2 had a
sensitivity of 97.7% and specificity of 77.9% for identifying normal versus abnormal
visual fields. SAP and SVOP v2 classifications showed complete agreement in 54% of
glaucoma patients, with a further 23% disagreeing by one category. On repeat
testing, 86% of SVOP v2 classifications agreed with the previous test, compared to
91% of SAP classifications; 71% of subjects preferred SVOP compared to 20% who
preferred SAP.
Conclusions: Eye-tracking perimetry can be used to obtain threshold visual field
sensitivity values in patients with glaucoma and produce maps of visual field defects,
with patterns exhibiting close agreement to SAP. Patients preferred eye-tracking
perimetry compared to SAP.
Translational relevance: This first report of threshold eye tracking perimetry shows
good agreement with conventional automated perimetry and provides a benchmark
for future iterations.
Introduction
Perimetry is central to the management of patients
with glaucoma, and is used to aid diagnosis, gauge
disease severity, and detect and measure rates of
progression. Automated threshold perimetry using a
white stimulus on a white background (standard
automated perimetry, SAP) has become the accepted
gold standard. SAP involves measuring the differen-
tial light sensitivity (DLS) at several test locations,
with algorithms used to vary stimulus brightness and
determine threshold values. Defining thresholds using
a full threshold test is time-consuming and onerous
for the patient, which can lead to reduction in test
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reliability and increased visit-to-visit variability.
Although testing times have been reduced significant-
ly using Swedish Interactive Threshold Algorithm
(SITA) strategies, the common perception of visual
field testing from patients is that it is difficult to
perform.
An investigation of patients’ opinions of tests used
in the management of glaucoma, found SAP to be the
least popular commonly performed procedure.1 Sim-
ilar findings have been reported recently using patient
focus groups, with patients expressing the opinion
that SAP was in need of modernization.2 In addition,
patients undergoing SAP have been found to experi-
ence higher levels of anxiety than those undergoing
other tests, such as retinal imaging, and those who
were anxious before undergoing SAP produced
poorer reliability test results.3 There is a need for a
more acceptable visual field test for patients.
Pioneering work by Damato has shown that the
visual field could be evaluated by moving the eye
rather than the test stimulus (oculokinetic perime-
try),4 but only recently have several groups explored
the possiblity of performing perimetry using comput-
erized eye tracking.5–8 Studies using eye tracking also
have shown that assessing the speed and accuracy of
saccadic eye movements also may be useful for
detecting disease, with differences in saccades noted
between healthy individuals and those with glauco-
ma.9–12 Eye tracking can be used to monitor patient
gaze responses to peripheral stimuli, with the advan-
tage that it does not require the patient to press a
response button. Additionally, by continually moni-
toring the patient’s eye location and adjusting the
position and size of the stimuli accordingly, perimetry
can be performed without the need for a chin rest. We
previously described a method of eye tracking
perimetry termed saccadic vector optokinetic perim-
etry (SVOP).13–16 SVOP initially was developed as a
suprathreshold test for children who struggle to
maintain fixation and produce the timely and reliable
responses needed for SAP. We recently developed a
threshold SVOP test and have shown that threshold
visual field sensitivities obtained using this device are
correlated closely with SAP threshold values.17 The
ability to perform threshold visual field testing using
an eye tracker has the potential to offer an alternative
method of perimetry to those who struggle with
conventional testing. In the present study we com-
pared patterns of visual field loss detected by SAP and
threshold SVOP and examined patient perceptions of
each technique.
Methods
This cross-sectional study included patients with
glaucoma and healthy subjects. Patients with glauco-
ma were recruited from a nonconsecutive series of
patients attending the glaucoma clinic at the Princess
Alexandra Eye Pavilion, Edinburgh. Healthy subjects
were required to have no previous history of
glaucoma or visual field defect and no neurologic
conditions that might affect the visual field. All
subjects provided written informed consent. The
study adhered to the tenets of the Declaration of
Helsinki and was approved by the South-East Scot-
land Research Ethics Committee, NHS Lothian.
Details of the inclusion and exclusion criteria have
been described previously.17
All patients attending the glaucoma clinic under-
went best-corrected visual acuity, slit lamp biomi-
croscopy, intraocular pressure measurement,
pachymetry, gonioscopy and dilated funduscopy.
The diagnosis of glaucoma was made by a glaucoma
specialist, based on the presence of typical glaucoma-
tous changes in optic disc morphology and a
glaucomatous visual field defect on SAP using the
Humphrey visual field analyzer (HFA) SITA Fast 24-
2 test (Carl Zeiss Meditec, Inc., Dublin, CA). All
subjects performed SAP and threshold SVOP in both
eyes and a random sample of subjects underwent
repeat SAP and SVOP testing in one eye during the
same session with suitable breaks if required. Patients
with strabismus or a history of eye movement
disorders were excluded. All patients had a best
corrected vision of better than 0.3 logMAR. In the
healthy group, eyes with a visual acuity worse than
0.15 logMAR were excluded.
SVOP Test
The threshold SVOP device has been previously
described.17 Threshold SVOP consists of a personal
computer with an examiner screen, a 24 00 high-
resolution LCD patient screen (Eizo ColorEdge
CG243W) and an eye tracker (IS-1 model; Tobii
Technology, Stockholm, Sweden; Fig. 1).
Patients were seated in front of the screen with
their eyes aligned with its center, at a testing distance
of approximately 55 cm, measured using an eye
tracking–based on-screen tool. Monocular testing was
performed using custom made test spectacles allowing
transferable, full aperture prescription lenses (55 mm
diameter) if required, while also occluding the nontest
eye with an infrared bandpass filter that enabled the
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Figure 1. Photo of the threshold SVOP device during testing and screen capture of the examiner screen during testing.
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eye tracker to detect the position of the occluded eye.
The test commenced with the patient fixating on a
central fixation stimulus. A test stimulus then was
presented peripherally. During testing, the patient was
instructed to follow their natural reaction to fixate
towards any peripheral stimulus perceived. The eye
tracker evaluated responses to the stimuli presented
on the display screen, and custom software deter-
mined whether stimuli had been perceived based on
the direction and amplitude of the subject’s gaze
response. The subject then was required to fixate on
the peripheral stimulus until another was perceived.
Stimuli were equivalent in size to Goldmann III and
each stimulus was presented for 200 ms using
coordinates equivalent to the SAP 24-2 test pattern.
The size and position of the stimuli were automati-
cally adjusted to compensate for changes in the
patient’s position during testing to ensure the
perceived stimulus size remained constant.
The screen was calibrated using a Look-Up Table
(LUT) pairing the grey-levels of each pixel to the
corresponding required background (10 Cd/m2) and
stimulus luminance levels. Stimuli luminance levels
replicated the luminance values corresponding to 14
to 40 dB on the HFA. Thresholds were obtained using
a 4-2 bracketing strategy and began by testing four
‘‘seed’’ locations (one in each quadrant), which then
were used to set the starting stimulus luminance levels
for neighboring locations, which in turn were used to
calculate the remaining starting luminance levels. The
SVOP threshold sensitivity values were matched in
luminance to those of the HFA to allow direct
comparison.
Before testing all subjects underwent a 20-second
demonstration. SVOP testing then began with a
calibration sequence, in which the subject was
required to follow a stimulus to nine different screen
locations to produce accurate eye gaze data during
testing. Incomplete SVOP and unreliable SAP tests
were excluded from analysis. An incomplete SVOP
test was any test that was stopped prematurely,
leaving any threshold values undetermined and an
unreliable SAP test was defined as a test with a false-
positive response rate exceeding 15%.
Questionnaire
On completion of testing, subjects were asked to
complete a short questionnaire regarding their expe-
rience and perceptions of SVOP and SAP. The
questionnaire consisted of three questions regarding
ease of test, perceived duration of testing, and test
comfort, with responses recorded using a 5-point
Likert scale. A final question asked patients to
indicate their preferred test (SVOP or SAP).
Modifications to SVOP During the Study
During the study, improvements were made to
version 1 (v1) of the SVOP software and version 2
(v2) was developed. Modifications included: (1) an
indicator of correct patient position, (2) an improved
interactive demonstration test, (3) an increased time
for determining fixation and a new fixation target
with central pulsating crosshairs to improve fixation,
and (4) modification of the starting luminance levels,
calculated from ‘‘seed’’ location and neighboring
location threshold levels to ensure they were never
below 18 dB. This ensured that threshold point results
would never be determined from a single stimulus
decision. Software v2 also included two bug fixes, one
relating to incorrect screen stimuli positions calculat-
ed under rare circumstances, and a second relating to
incorrect calculation of the starting luminance level
for one field point location. Subjects completing
testing using v1 and v2 were asked to complete the
questionnaire, however only results from software v2
were used for analysis of visual field defect patterns.
Data Analysis
To compare the patterns of visual field loss
detected by threshold SVOP and SAP, visual field
threshold sensitivity plots (greyscale) and sensitivity
values were reviewed by a panel of three graders (one
glaucoma specialist ophthalmologist and two research
optometrists experienced in glaucoma) who reached a
consensus on each visual field result. Grading was
performed in two batches, each batch corresponding
to a device, so that SVOP and SAP results from a
single patient were not performed consecutively.
Graders assigned visual fields into seven groups: 0,
normal; 2, paracentral; 3, nasal step; 4, arcuate; 5,
altitudinal; 6, biarcuate; and 7, end-stage field loss
(Fig. 2).18 The purpose of this classification was not to
represent the natural progression of glaucomatous
field loss, but rather to allow broad stratification of
different patterns of glaucomatous field loss. Graders
were permitted to assign visual field results to
multiple categories if more than one type of defect
was felt to be present. For example, a plot with
paracentral and arcuate loss could be classified as
categories 1 and 3.
The agreement between SVOP and SAP classifi-
cations, using the highest number category if more
than one was assigned, was compared qualitatively
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by cross-tabulation. Sensitivity and specificity of
SVOP (v1 and v2) were calculated by comparison of
normal (category 0) and abnormal (all other
categories) results using SAP as the reference
standard. The agreement between SVOP v1 and v2
and SAP also was assessed qualitatively by cross-
tabulation. A random subset of patients underwent
repeat SAP and SVOP testing to determine whether
the patterns of visual field loss detected using each
device were repeatable. Repeated results were cross-
tabulated and performance assessed using descrip-
tive statistics.
For group comparison tests, normality assumption
was assessed by inspection of histograms and using
Shapiro-Wilk tests. For comparison of two groups,
Student’s t-tests were used for normally distributed
variables and the Wilcoxon rank-sum test for
continuous nonnormal variables. For comparison of
more than two groups, 1-way analysis of variance
(ANOVA) was used. All tests were 2-sided and a P
value less than 0.05 was considered statistically
significant. Statistical analyses were performed with
SPSS version 21.
Results
The study included 59 healthy subjects and 103
with glaucoma. Healthy subjects were younger than
those with glaucoma (65.7 6 5.8 vs. 70.6 6 8.79
years, respectively; P , 0.001). Table 1 summarizes
the number of SAP and SVOP tests by subject,
including the number of tests excluded due to
incomplete tests or poor reliability. A total of 99
subjects underwent 191 SVOP v1 tests and 63
underwent 124 SVOP v2 tests. Of the 191 SVOP v1
tests, 39 (20%) were excluded due to inability to
complete the test, decreasing to 5 of 124 tests (4%)
with improvements in the SVOP software (v2).
Following exclusion of incomplete and poor reliabil-
ity tests, 142 comparison pairs (equivalent SVOP and
SAP tests) for SVOP v1 and 111 comparison pairs for
SVOP v2 were available for analysis.
Visual Field Defect Classification
Using the broad classification of normal (category
0) or abnormal (any other category), the sensitivity
Figure 2. The patterns of visual field loss used for classification in the study. Adapted from the study of Broadway.18
Table 1. Number of Subjects and Tests (SVOP v1, v2 and SAP) Performed (Excluding Repeat Tests), the Number
(and Reason) of Excluded Tests and the Resultant Comparison Test Pairs Used for Analysis
SVOP
Version Subject N




Incomplete (% of Total) Total
Excluded because
Unreliable (% of Total)
SVOP v1 Glaucoma 67 128 23 (18) 134 8 (6) 98
Healthy 32 64 16 (25) 64 7 (11) 44
Total 99 192 39 (20) 198 15 (8) 142
SVOP v2 Glaucoma 36 70 5 (7) 72 4 (6) 61
Healthy 27 54 0 (0) 54 4 (7) 50
Total 63 124 5 (4) 126 8 (6) 111
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and specificity of SVOP were determined using SAP 
as the reference standard. The 2 3 2 contingency table 
for SVOP v2 is shown in  Table 2, showing a 
sensitivity of 97.7% and specificity of 77.9% for 
SVOP v2 compared to SAP. SVOP v1 had a 
sensitivity of 95.3% and specificity of 61.0%.
The detailed cross tabulation of the visual field 
defect categories between SVOP v2 and SAP is shown 
in Table 3 with figures in bold showing the number of 
cases where agreement occurred. A total of 61 test 
pairs (SAP and SVOP v2) were available in patients 
with glaucoma, with complete agreement in classifi-
cation found in 33 (54%) and a further 14 (23%) 
disagreeing by one category. SVOP v1 had similar 
agreement, with complete agreement in 23 (69%) cases 
and disagreement by only one category in 14 (14%). 
The full cross-tabulation results for SVOP v1 are 
shown in the Supplementary Material. Supplementary 
Figure S1 shows several examples of threshold visual 
fields obtained from SAP and SVOP for patients 
included in the study.
Repeatability of SVOP and SAP Pattern 
Classifications
Table 4 shows the number of subjects who 
underwent repeat SVOP and SAP testing, including 
the number of tests excluded due to incompleteness or 
poor reliability.
Repeat field tests were compared to the initial tests 
for each patient and the agreement in classification of 
pattern of field defect was compared (Table 5). SVOP 
v2 had similar reproducibility compared to SAP, with 
86% and 91% showing complete agreement respec-
tively.
Acceptability
The results of the patient questionnaire examining 
test preferences are shown in Figures 3 to 6. A greater 
proportion of participants, and particularly those 
with glaucoma, reported SAP to be hard or relatively 
hard to perform compared to SVOP (v1 and v2).
Although SVOP took longer than SAP, most patients
thought the test time was ‘‘just right.’’ Figure 5 shows
the patients’ opinion on how comfortable they were
during testing. Of the patients and healthy subjects,
36% and 74% , respectively, found SAP to be ‘‘very
comfortable’’ or ‘‘relatively comfortable,’’ compared
to 91% and 88%, respectively, for SVOP. The
majority of subjects (71%) preferred SVOP, while
9% had no preference, and 20% preferred SAP (Fig.
6).
Discussion
Our study showed that SVOP can be used to
obtain threshold visual field sensitivity values in
patients with glaucoma and produce maps of visual
field defects with patterns exhibiting good agreement
with SAP. This is an exciting finding as SVOP has the




Abnormal 42 15 Positive predictive value ¼ 73.6%
Normal 1 53 Negative predictive value ¼ 98.1%
Sensitivity ¼ 97.7% Specificity ¼ 77.9%
Table 3. Comparison of Clinical Visual Field






Total0 1 2 3 4 5 6
Glaucoma group
0 10 0 0 1 0 0 0 11
1 4 1 1 0 0 0 0 6
2 0 0 1 0 0 0 0 1
3 4 1 4 20 2 0 0 31
4 0 0 0 3 0 0 0 3
5 0 0 0 1 0 0 0 1
6 0 0 0 4 3 0 1 8
Total 18 2 6 29 5 0 1 61
Healthy group
0 43 0 0 0 0 0 0 43
1 6 0 0 0 0 0 0 6
3 1 0 0 0 0 0 0 1
Total 50 0 0 0 0 0 0 50
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major advtange over SAP of being a totally objective
test of visual function sindce it does not rely on a
subjective patient response. Additionally, it negates
the requirement of the patient to press a response
button. Therefore, SVOP represents a potentially
important new test for the evaluation of the visual
field. An additional benefit is the finding that 71% of
participants preferred SVOP to conventional SAP
testing.
We used two versions of the SVOP software, with
v2 found to be superior to v1, which is now retired.
Compared to the gold standard of SAP, SVOP v2
correctly identified 42 of 43 abnormal visual fields,
which equates to a sensitivity of 97.7%. Of 68 normal
visual fields on SAP, 15 were identified as abnormal
on SVOP v2. This indicated a specificity of 77.9% for
SVOP compared to SAP SITA-fast; however, some of
the normal SITA-fast tests might have been false-
negatives. The study population for SVOP v2 testing
included 70 eyes with glaucoma, of which 67 (95.7%)
were identified as abnormal by SVOP and only 43
(61.4%) by SITA-fast (Table 2). Patients categorized
as having glaucoma had an established clinical
diagnosis by a glaucoma specialist based on the
presence of glaucomatous optic disc changes and a
visual field defect on SAP. Arguably, this is more
meaningful than the results of an isolated SAP test,
suggesting that many of the normal SITA-fast tests
may have been false-negatives; for example, fellow
eyes not yet manifesting glaucomatous field loss using
an isolated SAP SITA-fast test. This hypothesis needs
further testing as a limitation of the study was the lack
of an independent reference standard for diagnosis.
We also found good agreement between patterns of
field loss detected by SAP and SVOP. SVOP v2
produced visual field maps that were assigned to the
same category as SAP for 76 of 111 (68%) eyes, with a
further 20 (18%) differing by only one category. Only
15 of 111 tests (14%) differed by more than one
category. For those cases where SAP and SVOP did
not agree, the SVOP visual field tended to be graded
with a higher number, normally indicating more severe
visual field loss with 31 of 35 (89%) higher and 4 of 35
(11%) lower than SAP. The most frequent disagree-
ment was normal (category 0) on SAP being classified
as 1 or 3 by SVOP, and SAP category 3 or 4 being
classified as 6 by SVOP. The tendancy for SVOP to
produce results suggestive of a worse visual field than
SAP is likely due to the difficulty of detecting small eye
movements using the eye tracker, which may cause
some inaccuracies in precise mapping of the central
visual field in particular. Although the patient may
Table 4. Number of Subjects Performing Repeat SVOP or SAP with Resulting Number of Repeat Pairs Used for






or Unreliable (% of Total)
SVOP v1 Glaucoma 38 76 6 (8) 32
Healthy 30 60 9 (16) 21
Total 68 136 3 (2) 65
SVOP v2 Glaucoma 11 22 0 (0) 11
Healthy 10 20 0 (0) 10
Total 21 42 0 (0) 21
SAP Glaucoma 49 98 8 (8) 42
Healthy 40 80 8 (10) 34
Total 89 178 16 (9) 76







Number (%) Disagreeing by
More Than One Category
SAP 76 69 (91%) 3 (4%) 4 (5%)
SVOP v1 53 36 (68%) 14 (26%) 3 (6%)
SVOP v2 21 18 (86%) 2 (10%) 1 (5%)
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perceieve and move fixation to a central stimulus, there
may be instances where the eye tracker fails to detect
this movement, resulting in an apparent scotoma that
is not present on SAP. This finding also is supported
by our separate analysis of agreement between SAP
and SVOP threshold values, which found overall good
agreement between these values, but poorer correlation
between sensitivities in the central test locations.17
However, it is possible that some cases of apparantly
worse visual fields on SVOP compared to SAP were
due to earlier detection of damage using SVOP.
We found SVOP v2 to be superior than v1 and it is
likely that further improvements are possible, partic-
ularly through software refinements and improvements
in eye tracking technology. Towards the end of the
study, an improved eye tracker became available (X2-
60; Tobii Technology), with a higher sampling
frequency (60 Hz compared to a variable 25–40 Hz
Figure 4. Participant perceived test duration for SVOP and SAP.
Figure 3. Participant perceived ease of performing SVOP (v1 and v2) and SAP.
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used for the eye tracker used in v1 and v2). We
subsequently evaluated the improved eye tracker (using
software version 2) in 15 subjects (10 glaucoma
patients, 5 healthy subjects), 11 of whom had
experienced problems with the eye tracker and had
incomplete tests during original testing. All 15 patients
produced a complete test with 100% agreeing with the
visual field defect classification from SAP. The results
of testing in these 15 patients (available in full as
Supplementary Material) suggest that further improve-
ments in technology may reduce the number of
incomplete tests and improve agreement with SAP;
however, further studies are needed. We can speculate
that improvements have been made to the hardware
and firmware used by the eye tracker; however, these
improvements are proprietary to the eye tracking
company and it is not known exactly what factors
contributed to the improved eye tracking other than an
increased sampling rate.
Although disagreement may be reduced by im-
provements in hardware and software, some disagree-
ment between SVOP and SAP may be expected due to
the different methodologies to assess the visual field.
SVOP uses a one-dimensional response (visual recog-
nition) compared to the two-dimensional response
used by SAP; that is, visual recognition and a following
motor component (button press) and it is possible that
this different methodology itself could have an
influence in the measurement. Additionally, subjects
were tested using the HFA ‘‘SITA Fast’’ thresholding
algorithm, which is known to have larger test–retest
variability than the ‘‘SITA Standard’’ algorithm.
SVOP has some additional limitations, especially
that the current display screen is unable to display
stimuli brighter than 14 dB and that the current
testing algorithm takes signficantly longer than SAP
SITA Fast.17 However, despite the longer test time,
there was little difference in how the participants
perceived the testing time, with most subjects scoring
Figure 6. Participant preference regarding test type (SAP or
SVOP).
Figure 5. How comfortable the subject felt while performing SAP or SVOP testing.
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the time ‘‘just right’’ for both tests (Fig. 4). Patients
and healthy subjects found SVOP to be easier and
more comfortable to perform than SAP, a likely
reason why the SVOP testing time did not ‘‘feel’’
unnecessarily long. It is possible that patients with
glaucoma, who may be weary from repeated SAP
tests, may have preferred SVOP due to its novelty;
however, we also found that ‘‘perimetry naı¨ve’’
healthy subjects preferred SVOP to SAP.
Other limitations included the inability to complete
tests, usually due to problems with the eye tracker,
which also may struggle to function in patients with
high refractive error. However, we found the newer
iteration of SVOP software, and the new eye tracker
could overcome this problem. The use of a faster
sampling eye tracker also opens the intriguing
possibility of analyzing saccadic latency during an
SVOP test, which may provide a novel method of
assessing the impact of glaucoma on visual function.
Previous studies have found patients with glaucoma
to have delayed saccadic latency compared to healthy
subjects.6,9,10 For example, Mazumdar et al.6 used eye
movement perimetry to evaluate saccadic reaction
times to stimuli presented at locations corresponding
to the 54 test points of SAP.6 Patients with glaucoma
had prolonged saccadic reaction times, with a trend
towards increasing reaction times with increasing
disease severity. Further work is needed; however,
there may be the potential to quantify saccades to
provide additional information to assist with diagno-
sis and monitoring.
In conclusion, we demonstrated an alternative
method of measuring threshold visual fields that is
repeatable and compares well with the current gold
standard when considering the clinically relevant visual
field pattern produced. It has advantages of being
ergonomically preferred with no postural constraints,
allows dynamic fixation, and uses a natural inherent
reflex. We also have demonstrated that improvements
can be made through iteration (in hardware and
software). Further work is required to evaluate SVOP
v3 on a larger cohort of subjects while also collecting
useful normative threshold data and saccadic latency
data in glaucoma patients and healthy subjects.
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